IL278019A - trans splicing molecules - Google Patents
trans splicing moleculesInfo
- Publication number
- IL278019A IL278019A IL278019A IL27801920A IL278019A IL 278019 A IL278019 A IL 278019A IL 278019 A IL278019 A IL 278019A IL 27801920 A IL27801920 A IL 27801920A IL 278019 A IL278019 A IL 278019A
- Authority
- IL
- Israel
- Prior art keywords
- trans
- splicing molecules
- splicing
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/85—Fusion polypeptide containing an RNA binding domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658667P | 2018-04-17 | 2018-04-17 | |
| US201862658658P | 2018-04-17 | 2018-04-17 | |
| PCT/US2019/027981 WO2019204514A1 (en) | 2018-04-17 | 2019-04-17 | Trans-splicing molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL278019A true IL278019A (en) | 2020-11-30 |
Family
ID=68239871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL278019A IL278019A (en) | 2018-04-17 | 2020-10-13 | trans splicing molecules |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11993776B2 (enExample) |
| EP (1) | EP3781213A4 (enExample) |
| JP (2) | JP7561624B2 (enExample) |
| KR (2) | KR102866133B1 (enExample) |
| CN (1) | CN112449605A (enExample) |
| AU (1) | AU2019255708B2 (enExample) |
| BR (1) | BR112020021228A2 (enExample) |
| CA (1) | CA3097004A1 (enExample) |
| IL (1) | IL278019A (enExample) |
| MX (2) | MX2020010959A (enExample) |
| WO (1) | WO2019204514A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102866133B1 (ko) | 2018-04-17 | 2025-09-30 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 트랜스-스플라이싱 분자 |
| BR112021020539A2 (pt) * | 2019-04-17 | 2022-01-04 | Univ Pennsylvania | Terminador de hélice tripla para trans-splicing de rna eficiente |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| AU2022337146A1 (en) | 2021-09-03 | 2024-03-14 | Tacit Therapeutics, Inc. | Rna editing via recruitment of spliceosome components |
| EP4522758A4 (en) * | 2022-05-13 | 2026-05-06 | Ascidian Therapeutics Inc | Abca4 trans-splicing molecules |
| US20260007773A1 (en) * | 2022-07-07 | 2026-01-08 | Aldevron, Llc | Ocular vectors and uses thereof |
| EP4594505A1 (en) * | 2022-09-30 | 2025-08-06 | Centre National de la Recherche Scientifique | Therapy by trans-splicing of opa1 pre-messenger rnas for the treatment of diseases associated with opa1 gene mutations |
| KR20250157548A (ko) * | 2023-02-15 | 2025-11-04 | 아시디엔 테라퓨틱스, 인크. | Htt 트랜스 스플라이싱 분자 |
| WO2025166360A1 (en) * | 2024-02-03 | 2025-08-07 | Duke University | Compositions for and methods of engineering the transcriptome |
| WO2026012439A1 (en) * | 2024-07-11 | 2026-01-15 | Sichuan Real & Best Biotech Co., Ltd. | Rna trans-splicing molecules and systems |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE354957T1 (de) | 1995-12-15 | 2006-03-15 | Intronn Inc | Durch trans-spaltung erhaltene therapeutische molekule |
| US6280978B1 (en) | 1995-12-15 | 2001-08-28 | Intronn Holdings, Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| AU735272B2 (en) | 1996-10-04 | 2001-07-05 | Intronn Llc | Sample collection devices and methods using markers and the use of such markers as controls in sample validation, laboratory evaluation and/or accreditation |
| US6929907B2 (en) | 1999-12-31 | 2005-08-16 | North Carolina State University | Methods and compositions for determining the purity of chemically synthesized nucleic acids |
| JP4500540B2 (ja) | 2001-06-29 | 2010-07-14 | ヴェリ‐キュー，インコーポレイテッド | 化学的に合成された核酸の純度を決定し、かつ化学的に合成された核酸を精製するための方法および組成物 |
| AU2003215249B2 (en) | 2002-02-12 | 2008-07-03 | Virxsys Corporation | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| CA2477295A1 (en) | 2002-02-25 | 2003-09-04 | Intronn, Inc. | Trans-splicing mediated imaging of gene expression |
| US7399753B2 (en) | 2002-02-25 | 2008-07-15 | Virxsys Corporation | Trans-splicing mediated photodynamic therapy |
| AU2003247505A1 (en) | 2002-06-05 | 2003-12-22 | University Of Iowa Research Foundation | Spliceosome mediated rna trans-splicing in stem cells |
| EP1521766B1 (en) | 2002-06-05 | 2012-11-07 | VIRxSYS Corporation | SPLICEOSOME MEDIATED RNA i TRANS /i -SPLICING AND CORRECTION OF FACTOR VIII GENETIC DEFECTS USING SPLICEOSOME MEDIATED RNA TRANS SPLING |
| US20040018622A1 (en) | 2002-07-17 | 2004-01-29 | Mitchell Lloyd G. | Spliceosome mediated RNA trans-splicing for correction of skin disorders |
| EP1579004B1 (en) | 2002-10-23 | 2010-06-16 | VIRxSYS Corporation | Screening methods for identification of efficient pre-trans-splicing molecules |
| EP1716165A4 (en) | 2004-01-23 | 2008-06-18 | Virxsys Corp | EXPRESSION OF APOA-1 AND VARIANTS THEREOF, USING SPSSISSOSOM-MEDIATED RNA TRANS MIXING |
| US8053232B2 (en) | 2004-01-23 | 2011-11-08 | Virxsys Corporation | Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing |
| WO2006026611A2 (en) | 2004-08-31 | 2006-03-09 | Mitchell Lloyd G | Reverse transcriptase mediated rna gene expression |
| US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| US20090214478A1 (en) | 2008-02-21 | 2009-08-27 | Alberto Auricchio | Method of treating ocular diseases by gene therapy |
| US8236557B2 (en) | 2008-05-28 | 2012-08-07 | University Of Missouri-Columbia | Hybrid-AAV vectors to deliver large gene expression cassette |
| EP2151248A1 (en) | 2008-07-30 | 2010-02-10 | Johann Bauer | Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses |
| AU2013234376B2 (en) * | 2008-10-22 | 2016-07-28 | Acucela, Inc. | Compounds for treating ophthalmic diseases and disorders |
| US8648053B2 (en) | 2010-10-20 | 2014-02-11 | Rosalind Franklin University Of Medicine And Science | Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome |
| US9249425B2 (en) | 2011-05-16 | 2016-02-02 | The Trustees Of The University Of Pennslyvania | Proviral plasmids and production of recombinant adeno-associated virus |
| EP2753694B1 (en) * | 2011-09-05 | 2017-08-23 | Stichting Katholieke Universiteit | Antisense oligonucleotides for the treatment of leber congenital amaurosis |
| EP2872183B1 (en) | 2012-07-11 | 2018-09-26 | The Trustees Of The University Of Pennsylvania | Aav-mediated gene therapy for rpgr x-linked retinal degeneration |
| US9717749B2 (en) | 2012-10-16 | 2017-08-01 | Massachusetts Institute Of Technology | Production of stable non-polyadenylated RNAs |
| GB201219762D0 (en) | 2012-11-02 | 2012-12-19 | Bauer Johann | A RNA trans-splicing molecule (RTM) for use in the treatment of cancer |
| US10266845B2 (en) | 2013-02-08 | 2019-04-23 | The Trustees Of The University Of Pennsylvania | Enhanced AAV-mediated gene transfer for retinal therapies |
| US9567376B2 (en) | 2013-02-08 | 2017-02-14 | The Trustees Of The University Of Pennsylvania | Enhanced AAV-mediated gene transfer for retinal therapies |
| AU2014255665B2 (en) * | 2013-04-18 | 2018-08-02 | Fondazione Telethon | Effective delivery of large genes by dual AAV vectors |
| US10155794B2 (en) | 2013-07-16 | 2018-12-18 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of disorders related to CEP290 |
| ES2745769T3 (es) | 2014-03-10 | 2020-03-03 | Editas Medicine Inc | Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10) |
| DK3167076T3 (da) | 2014-07-09 | 2022-02-21 | Lexogen Gmbh | Fremgangsmåder og produkter til kvantificering af RNA-transkriptvarianter |
| SI3265571T1 (sl) * | 2015-03-03 | 2022-10-28 | Fondazione Telethon | Več vektorski sistem in njegove uporabe |
| CA3005474A1 (en) * | 2015-11-19 | 2017-05-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for correction of heritable ocular disease |
| JP7036723B2 (ja) * | 2015-12-14 | 2022-03-15 | コールド スプリング ハーバー ラボラトリー | 眼疾患の処置のための組成物および方法 |
| SG11202000840YA (en) * | 2017-07-31 | 2020-02-27 | Reflection Biotechnologies Ltd | Cellular models of and therapies for ocular diseases |
| WO2019027869A1 (en) | 2017-07-31 | 2019-02-07 | Massachusetts Institute Of Technology | RNA-CLUSTER INDUCED TRANSCRIPT STABILIZER AND USES THEREOF |
| KR102866133B1 (ko) | 2018-04-17 | 2025-09-30 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 트랜스-스플라이싱 분자 |
| BR112021020539A2 (pt) | 2019-04-17 | 2022-01-04 | Univ Pennsylvania | Terminador de hélice tripla para trans-splicing de rna eficiente |
| WO2020214990A1 (en) | 2019-04-17 | 2020-10-22 | Ascidian Therapeutics, Inc. | Abca4 cell line and methods of use |
| EP3962295A1 (en) | 2019-05-01 | 2022-03-09 | The Procter & Gamble Company | Probiotic bacterial strains that produce short chain fatty acids and compositions comprising same |
| EP4522758A4 (en) | 2022-05-13 | 2026-05-06 | Ascidian Therapeutics Inc | Abca4 trans-splicing molecules |
-
2019
- 2019-04-17 KR KR1020207032936A patent/KR102866133B1/ko active Active
- 2019-04-17 CN CN201980040706.1A patent/CN112449605A/zh active Pending
- 2019-04-17 US US17/047,496 patent/US11993776B2/en active Active
- 2019-04-17 BR BR112020021228-8A patent/BR112020021228A2/pt unknown
- 2019-04-17 WO PCT/US2019/027981 patent/WO2019204514A1/en not_active Ceased
- 2019-04-17 KR KR1020257032132A patent/KR20250150157A/ko active Pending
- 2019-04-17 JP JP2020557945A patent/JP7561624B2/ja active Active
- 2019-04-17 CA CA3097004A patent/CA3097004A1/en active Pending
- 2019-04-17 EP EP19789043.7A patent/EP3781213A4/en active Pending
- 2019-04-17 MX MX2020010959A patent/MX2020010959A/es unknown
- 2019-04-17 AU AU2019255708A patent/AU2019255708B2/en active Active
-
2020
- 2020-10-13 IL IL278019A patent/IL278019A/en unknown
- 2020-10-15 MX MX2025007209A patent/MX2025007209A/es unknown
-
2024
- 2024-04-30 JP JP2024073380A patent/JP2024099770A/ja active Pending
- 2024-05-24 US US18/673,713 patent/US12442003B2/en active Active
-
2025
- 2025-09-17 US US19/331,448 patent/US20260078380A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020021228A2 (pt) | 2021-03-02 |
| JP7561624B2 (ja) | 2024-10-04 |
| US20210155938A1 (en) | 2021-05-27 |
| CA3097004A1 (en) | 2019-10-24 |
| US11993776B2 (en) | 2024-05-28 |
| JP2021520837A (ja) | 2021-08-26 |
| MX2020010959A (es) | 2021-01-15 |
| EP3781213A1 (en) | 2021-02-24 |
| US12442003B2 (en) | 2025-10-14 |
| EP3781213A4 (en) | 2022-10-19 |
| MX2025007209A (es) | 2025-07-01 |
| KR102866133B1 (ko) | 2025-09-30 |
| AU2019255708B2 (en) | 2026-02-12 |
| US20260078380A1 (en) | 2026-03-19 |
| CN112449605A (zh) | 2021-03-05 |
| AU2019255708A1 (en) | 2020-11-26 |
| KR20250150157A (ko) | 2025-10-17 |
| US20240318186A1 (en) | 2024-09-26 |
| WO2019204514A1 (en) | 2019-10-24 |
| KR20210018222A (ko) | 2021-02-17 |
| JP2024099770A (ja) | 2024-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278019A (en) | trans splicing molecules | |
| GB201615617D0 (en) | Small molecules | |
| GB201612520D0 (en) | Binding molecules | |
| EP3371785A4 (en) | In-vehicle access application | |
| EP3331549A4 (en) | Improved microbe-binding molecules and uses thereof | |
| GB201521858D0 (en) | Small molecules | |
| AU201713736S (en) | Cartridge | |
| IL273493A (en) | Modified CAR-T | |
| EP3288580A4 (en) | Glycan-dependent immunotherapeutic molecules | |
| EP3250601A4 (en) | Multivalent molecules comprising dr5-binding domains | |
| GB201601075D0 (en) | Antibodies molecules | |
| GB201522391D0 (en) | Antibody molecules | |
| GB201702091D0 (en) | Specific binding molecules | |
| SG11201808538QA (en) | Trans-splicing rna (tsrna) | |
| ZA202001649B (en) | Rna molecules | |
| IL289266B1 (en) | New molecules | |
| PL3582629T3 (pl) | Marynata | |
| GB2563450B (en) | Cartridge | |
| GB201718538D0 (en) | u | |
| HK40048428A (en) | Trans-splicing molecules | |
| GB201919193D0 (en) | Novel molecules | |
| GB201912688D0 (en) | Novel Molecules | |
| GB201706043D0 (en) | Small molecules | |
| GB201706042D0 (en) | Small molecules | |
| HK40033373A (en) | Rna molecules |